ICBCCS CSI Brand Name Drug Industry ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

159859

516080

588130

510660

159992

512290

516060

512010

China is optimizing the pricing mechanism for newly launched medicines, allowing pharmaceutical companies to set prices based on clinical significance and R&D costs. The new policy supports firms in determining initial prices considering market demand and competition, while ensuring patient benefits are prioritized. It clarifies previous ambiguities in drug pricing and allows for stable prices for a certain period post-launch, reflecting a shift towards a market-led pricing mechanism for innovative drugs.

Yicai

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Innovative Drugs ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks

589720

159286

520970

159835

515120

159316

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

CCB Principal CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

GF CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

800医药

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

腾讯新闻 - 财经

Yinhua CNI HK Connect Innovative Drugs ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

600547

GDXW

588700

Last week (from March 30 to April 3), the Shanghai Composite Index slightly fell by 0.86%, while the growth style index was significantly adjusted downwards. The pharmaceutical commerce and precious metals sectors performed strongly, with the innovative drug ETF leading the gains, and the ICBC Innovative Drug ETF rising by 6.9%. Despite a net outflow of 4.042 billion yuan in the overall ETF market and an outflow of 12.117 billion yuan in equity ETFs, bond, commodity, and currency ETFs all achieved net inflows. The Hong Kong innovative drug market has stabilized, with low valuations and ample room for allocation, and the industry's fundamentals have improved, indicating that the subsequent market trend is expected to fluctuate upwards

SD-GOLD

Roundhill Gold Miners Weeklypay ETF

Harvest SSE STAR Biology and Medicine ETF

ZHONGJIN GOLD

GF CSI HK Innovative Drugs Industry ETF(QDII)

EFUND GOLD MI ETF

Pro Ultr GLD

SPDR GOLD TRT

Microsectors Gold Miners 3x Leveraged ETN

iShares MSCI Global Gold Miners

Direxion Daily Jr Gold Miners Bull 2X

GLOBAL X Gold Explorers

ChinaAMC Gold ETF

Direxion Daily Gold Miners Bull 2X

VanEck Gold Miners ETF

SPDR Gold Minishares

Sprott GLD Miners Etf

EFUND GOLD MI-U

Us Gbl GLD & Met

EFUND GOLD MI-R

YieldMax Gold Miners Opt Inc Strgy ETF

Sprott JR Gold Miners ETF

Zijin Mining

Abrdn Gold ETF Trust

ICBCCS CNI HK Connect Innovative Drugs ETF

ETF Weekly Review: Innovative Drugs Dominate the Rankings, Gold Strongly Attracts Capital

300149

On April 1st, all three major A-share indices rose by more than 1%, with innovative drug concept stocks collectively increasing, and multiple stocks such as ChemPartner hitting the daily limit. The upcoming 2026 American Association for Cancer Research Annual Meeting has become a catalyst for market enthusiasm. Huayuan Securities pointed out that China's pharmaceutical industry has completed the transition from generics to innovation, with innovative drugs becoming a new engine for industry growth. Future investments should focus on innovative drug companies with global competitiveness and cutting-edge technology directions

ChemPartner

April starts with a bang, the innovative drug concept collectively explodes, ChemPartner hits the 20% daily limit up

161122

The CSI Innovative Drugs Industry Index surged 11% over the past week. Brokerages believe the innovative drug sector is in a stage of "earnings realization, valuation repair, and conference catalysis." Multiple biopharmaceutical companies have achieved historic turnarounds, with fundamentals improving. In the first quarter of this year, the total amount of China's innovative drug out-licensing reached nearly $57 billion, already exceeding the full-year level of 2024. The upcoming AACR and ASCO annual meetings, with intensive clinical data disclosures, are expected to provide catalysts

E Fund CSI WD Biotechnology Index Fund(LOF)-A

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Wanjia CSI Hong Kong Connect Innovative Drugs ETF

Invesco Great Wall CSI Hong Kong Connect Innovative Drug ETF

Innovative Drugs Break Out Again After Six Months, Leading Companies Enter Intensive Harvest Period; Has the Profit Inflection Point Arrived?

In 2025, data on transactions involving the introduction of innovative drugs and technology platforms from China by the world's top 20 multinational pharmaceutical companies (MNCs) shows that the average total package amount reached USD 2.756 billion, with an average upfront payment of USD 236 million, which is approximately 114% and 54% higher than other regions globally. MNCs are willing to pay high prices for innovative assets mainly due to the impending patent cliff, with an estimated USD 236 billion worth of blockbuster drug patents set to expire by 2030. China's rapid R&D progress in areas such as ADC, bispecific antibodies, and cell therapy, along with its advantages of low cost and high efficiency, has attracted the attention of MNCs

Guotai Hang Seng Biotech ETF

China Universal CSI Biotechnology Theme Index Initiating Fund(LOF)-A

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

2025 MNC Introduces Trading Decoding: The Year of "Value Awakening" for Chinese Innovative Drugs

ICBCCS CSI Brand Name Drug Industry ETF(516060.SH)

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

ETF Weekly Review: Innovative Drugs Dominate the Rankings, Gold Strongly Attracts Capital